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Introduction 
The process of pluripotent stem cell 
differentiation was long thought to be 
unidirectional and irreversible. It was believed 
that progenitor cells became locked into a single 
lineage as they divided, eventually losing their 
capacity to differentiate into new cell types. 
This model was overturned with the discovery 
of induced pluripotent stem cells (iPSCs). The 
expression of four transcription factors, Oct4, 
Sox2, Klf4 and c-Myc, in mouse embryonic 
fibroblasts was shown to produce a small 
population (0.02% efficiency) of pluripotent 
stem cells [1]. Subsequent studies have 
demonstrated potential uses for this technique, 
including the generation of iSPCs from human 
fibroblasts [2-4], creating disease models by 
generating disease-specific iSPCs from 
individual patients [5-7], and bypassing many of 
the ethical dilemmas surrounding the use of 
embryonic stem cells. Advances in cellular 
reprogramming also led to the discovery that 
mouse embryonic fibroblasts (MEFs) could be 
directly converted into neurons by using the 
neural-associated factors Ascl1, Brn2 and Myt1L 
(BAM pool) [8]. Though similar to iPSC 
generation, directly reprogramming MEFs into 
induced neurons (iNs) was faster, more efficient 
(7-19%), and required fewer steps to form 
mature, functional neurons. These findings led 
to further experiments using human fibroblasts, 
which successfully generated iNs, though the 
addition of the factor NeuroD1 to the BAM pool 
was required [9-11]. 
With the BAM pool established as a 
foundation for direct neural reprogramming, 
researchers are now attempting to derive 
specific neuronal types. The BAM pool alone 
produces predominantly glutamatergic neurons 
[8], but additional factors have been found to 
induce the production of additional cell types, 
including dopaminergic neurons [12], tyrosine-
hydroxylase expressing cells [13], motor 
neurons [14], and neural progenitor cells [15-
16] (Fig. 1). It has not yet been determined what 
factors are necessary to enrich production of 
GABAergic neurons.  
The neurotransmitter γ-aminobutyric 
acid (GABA) is used as a primary inhibitory 
signal in a number of essential brain functions, 
including structural and functional development 
of the cortex [18], modulation of cortical output 
[19], and plasticity [20]. Abnormal GABAergic 
signaling has been linked to epilepsy [21-23], 
schizophrenia [24-26], autism spectrum disorder 
[27,28], and anxiety disorders [29]. Though the 
development and differentiation of GABAergic 
neurons is not fully understood (due in part to 
the diversity of GABAergic interneuron 
subtypes), several factors have been implicated 
in 5-HT-specific differentiation (Table 1). 
We examined these possible GABAergic 
factors to identify which, if any, are capable of 
directly reprogramming MEFs into GABAergic 
iNs. Simultaneously transfecting all nine factors 
plus the BAM pool resulted in cell death (data 
not shown). Thus, groups of four potential 
factors for determining GABAergic cell fate 
(Table 2) were combined with the BAM pool 
              Mouse Fibroblasts         Human Fibroblasts 
 
Figure 1: Established neural cell-reprogramming 
pathways. Each is listed with the necessary transcription 
factors; parentheses indicate alternative factors that yield 
the same cell type. Figure adapted from [17].  
Table 1: GABAergic Candidate Factors 
Transcription Factor References 
Lbx1 30, 31 
Pax2 19, 31 
Lhx1 32 
Lhx2 32 
Dlx1 19, 32-35 
Dlx2 19, 32-34, 36 
PitX2 37, 38 
Pft1a 31, 39-41 
 
Table 2: Transfection Groups 
Group # Factors 
1 BAM + Lbx1, Pax2, PitX2 
2 BAM + Lbx1, Pax2, Pft1a 
3 BAM + Lbx1, Dlx1, Lhx1 
4 BAM + Lbx1, Dlx2, Lhx2 
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and transfected into Tau-EGFP MEFs. Resulting 
iNs were tested for interneuron-specific markers 
to determine if these factors were sufficient to 
induce GABAergic neuronal cell fate. 
Individual factors were then removed in order to 
determine the minimum combination of factors 
necessary to generate GABAergic iNs. 
Methods 
Mouse embryonic fibroblast isolation & culture: 
Homozygous TauEGFP (Jackson Laboratories) 
MEFs [42] were isolated from E14 embryos 
under a dissection microscope (Olympus). The 
head, vertebral column (containing the spinal 
cord), dorsal root ganglia, and all internal 
organs were excised to ensure the removal of all 
potentially neurogenic cells from culture. The 
remaining tissue was dissociated in 0.5% trypsin 
at 37°C for 30 minutes. The resulting cell 
suspension was plated on 1x Gelatin-coated 6-
well plates in Fibroblast Media containing 
DMEM (Invitrogen), 10% FBS (Atlanta 
Biologicals), β-mercaptoethanol (Sigma), MEM 
NEAA, sodium pyruvate and 
penicillin/streptomycin (all Invitrogen). Cells 
were grown at 37˚C until confluent, and then 
frozen. Upon thawing, cells were grown in 
antibiotic-free Fibroblast Media until confluent, 
at which point the cells were transfected. The 
MEFs were transfected before their third 
passage. Two days after transfection, cells were 
passaged 1:4 and put onto laminin-coated 
coverslips. Five days after transfection cells 
were switched to Neural Differentiation Media, 
containing DMEM/F12 and supplemented with 
1% each N2, B27, and MEM NEAA, 0.1% 
Ascorbic Acid, and 0.01% each BDNF, GDNF 
and cAMP (all Invitrogen).  
Gene cloning & transfection: Eight transcription 
factors associated with GABAergic cell fate 
(Table 1) were chosen for transfection along 
with the BAM pool. Each factor was inserted 
into a plasmid, under the ubiquitous CAG 
promoter. The inserts were flanked with 
terminal repeats; upon the addition of PiggyBac 
transposase (PBase), the cDNA between these 
flanking repeats was excised and inserted into 
the fibroblast genome. Without PBase, the 
plasmids remain episomal, with no genomic 
incorporation. Plasmid cDNA transfection was 
carried out using FuGene6 (Roche). The reagent 
was first diluted in Opti-MEM basal media 
(Invitrogen) at a 3:100 ratio, and then incubated 
at room temperature for 5 minutes.  Plasmid 
DNA was then added to the solution at a ratio of 
1 µg of DNA for every 3 µL FuGene6. This was 
incubated at room temperature for 15 minutes. 
100 µL of complex was added to the Fibroblast 
Media in each well of a 6 well plate.  Media was 
changed 24 hours after transfection. 
Immunocytochemistry & cell counts: Cells were 
fixed in 4% paraformaldehyde for 12 minutes at 
room temperature. After washing, cells were 
treated with blocking solution containing 0.2% 
TritonX-100 (Sigma) and 5% goat serum 
(Sigma) for 30 minutes at room temperature. 
Primary and secondary antibodies were diluted 
in blocking solution. Typically, primary and 
secondary antibodies were applied for one hour 
and 30 minutes, respectively, both at room 
temperature.  Between primary and secondary 
staining cells were washed three times with 
PBS. The following antibodies were used: rabbit 
anti-GABA (Sigman, 1:4,000), mouse anti-
MAP2 (Sigma, 1:500), mouse anti-NeuN 
(Millipore, 1:100), rabbit anti-Tuj1 (Covance, 
1:1,000), mouse anti-Tuj1 (Covance, 1:1,000), 
guinea-pig anti-vGLUT1 (Millipore, 1:2,000). 
Alexa-488- and Alexa-568-conjugated 
secondary antibodies were obtained from 
Inivitrogen. Cells were kept in neural media for 
1-4 weeks prior to paraformaldehyde fixation 
and ICC analysis. 
Efficiency calculation: Efficiency of neuronal 
induction was calculated between 7 and 20 days 
after transfection. The total number of Tuj1+ 
cells with neuronal morphology (circular, three-
dimensional appearance with thin processes at 
least three times longer than width of the cell 
body) found on 10 different 6-well coverslips 
were quantified. This number was divided by 
the number of cells plated before transfection to 
get the percentage of the starting cell population 
that adopted neuron-like properties. Efficiency 
of GABAergic reprogramming was calculated 
by dividing the number of GABA+ iNs by the 
total number of Tuj1+ cells.  
 










 Twenty days after transfection, all 
coverslips contained Tuj1+ iN cells with 
subpopulations of GABA+ cells. A marked 
difference in GABA+ cells was found between 
groups 1, 3, and 4, compared to controls (Fig. 
2). No notable difference was seen between 
group 2 and controls, though these results 
differed considerably from preliminary 
experiments (data not shown).  
Several groups of factors enriching for 
interneuron production led to further 
transfections, in which each group of factors 
was broken first into pairs, then individual 
factors. This would elucidate the role of the 
individual factors in GABAergic iN production.  
In order to assess the validity of the initial group 
2 findings, the factors that formed group 2 were 
the first to be re-grouped and added to the BAM 
pool. Component factors were transfected 
individually and in pairs, along with the BAM 
pool (Fig. 3). Individual and paired group 2  
 
factors resulted in noticeably higher yields of 
GABA+ cells, with the combination of Pax2 and 
Pft1a producing the greatest percentage of 
GABA+ iNs. Pax2 alone failed to produce 
comparably high derivation of GABA+ cells, but 
Pft1a alone did result in an increased percentage 
of GABA+ iNs compared to controls. 
Discussion 
 Groups containing all eight transcription 
factors of interest have demonstrated some 
capacity for enriching production of GABA+ 
iNs, though the most efficient factor 
combination must still be determined. Of every 
group of factors tested here, group C yielded the 
highest percentage of GABA+ neurons. The fact 
that this combination (BAM + Pax2, Pft1a) was 
derived from the least efficient of the initial 
groups indicates that more experiments will be 
necessary to elucidate which factors are required 
to generate GABA+ iNs. 
 The enhanced enrichment of GABA+ 
cells in groups C and F indicate that Pft1a may 
Figure 3: Factors in Group 2 were transfected 
individually and in pairs (table). Efficiency of GABA+ 
expression following transfection with groups A-F 
(graph). Error bars represent standard error across all 
trials (n=3; n=4 for PB+F). PB+D cells did not survive 
to transfection date. 
Condition Factors 
A BAM + Lbx1, Pax2 
B BAM + Lbx1, Pft1a 
C BAM + Pax2, Pft1a 
D BAM+ Lbx1 
E BAM + Pax2 
F BAM + Pft1a 
 
Figure 2: Some induced neurons displayed the 
interneuron marker GABA (A), while others remained  
Glutamatergic in appearance (B). (C) Efficiency of 
GABA+ expression following transfection with groups 
1-4. Error bars represent standard error across all trials 
(n=3). PB+2 coverslips included non-neuronal 
material, confounding cell counts.  
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play a crucial role in determining interneuron 
cell fate. The addition of Pax2 alone to the 
BAM pool did not greatly increase the percent 
yield of GABA+ cells. When Pax2 and Pft1a 
were added together, however, a greater 
percentage of GABA+ iNs were generated than 
when Pft1a was added alone. As a result Pax2 
cannot be discounted as a potential factor for 
enrichment of GABA+ iNs, and must be further 
studied along with Pft1a. 
 Additional experiments will be required 
to fully characterize the effects of these target 
factor pools. Factors from the other three groups 
must be transfected individually and in pairs in 
order to discover which factors yield the 
greatest GABAergic iN enrichment, most likely 
including Pft1a. Once all maximizing factors 
are identified, removal of individual BAM 
factors from the transfection pool will determine 
if these novel factors are sufficient to replace 
any of the BAM factors and still induce 
neuronal reprogramming. Electrophysiological 
analysis will elucidate the functionality of these 
GABA+ iNs, and interneuron-specific 
immunostaining will identify any interneuron 
subtypes generated by these factors.  
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